Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis.
about
Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney diseaseDaclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-AnalysisDaclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis.NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study.The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients.The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings.Hepatitis C Virus Clearance in Older Adults.Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b.Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments.Efficacy and safety of sofosbuvir and ledipasvir in Japanese patients aged 75 years or over with hepatitis C genotype 1.Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia.
P2860
Q28077263-E603B699-3BAC-419A-8B16-A1C3EB5F4C02Q28077287-71EC09AA-299F-4F76-9AD9-747DD58E3CC4Q38755098-E41433A1-4D7A-4043-9489-6DDBEA52695BQ38946893-2AB92C10-E5F4-4982-9B8A-ABCBE2968E8DQ39134413-12C542CC-C2B9-4B33-AB02-B293CA29B65BQ40080544-A3228A68-1262-446C-A0AF-7B82339DDD28Q40086558-AA452523-551B-4650-AD00-4D2ABC2B6A42Q40340001-FE4BB9F8-8550-4443-BC83-8358F0CBC20FQ45324869-C2E9ED74-8229-4F89-9BDC-45A6B3616727Q47121490-F72127AF-EBF3-40F8-915B-91376BC9A578Q47595176-7D306B1B-9673-464C-819F-A7ED4DA50E4BQ47642315-01DC830C-20F0-4BAB-B5E9-AA0DC01275C5Q47657221-72E1FD8A-8469-49FF-8543-462C7EC32EB1
P2860
Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Effectiveness and safety of da ...... ver with or without cirrhosis.
@en
type
label
Effectiveness and safety of da ...... ver with or without cirrhosis.
@en
prefLabel
Effectiveness and safety of da ...... ver with or without cirrhosis.
@en
P2093
P2860
P356
P1433
P1476
Effectiveness and safety of da ...... ver with or without cirrhosis.
@en
P2093
Akira Kawano
Eiichi Ogawa
Eiji Kajiwara
Hideyuki Nomura
Jun Hayashi
Kazufumi Dohmen
Kazuhiro Kotoh
Kazuhiro Takahashi
Koichi Azuma
Kyushu University Liver Disease Study(KULDS) Group
P2860
P304
P356
10.1111/HEPR.12738
P577
2016-05-03T00:00:00Z